KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Net Income (2016 - 2025)

Historic Net Income for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $51.2 million.

  • Emergent BioSolutions' Net Income fell 5540.07% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.9 million, marking a year-over-year increase of 13635.06%. This contributed to the annual value of -$190.6 million for FY2024, which is 7493.75% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Net Income of $51.2 million as of Q3 2025, which was down 5540.07% from -$12.0 million recorded in Q2 2025.
  • Emergent BioSolutions' Net Income's 5-year high stood at $177.9 million during Q4 2021, with a 5-year trough of -$283.1 million in Q2 2024.
  • In the last 5 years, Emergent BioSolutions' Net Income had a median value of -$31.3 million in 2024 and averaged -$44.1 million.
  • Per our database at Business Quant, Emergent BioSolutions' Net Income skyrocketed by 65760.0% in 2021 and then plummeted by 493243.24% in 2023.
  • Emergent BioSolutions' Net Income (Quarter) stood at $177.9 million in 2021, then tumbled by 137.66% to -$67.0 million in 2022, then rose by 26.12% to -$49.5 million in 2023, then soared by 36.77% to -$31.3 million in 2024, then skyrocketed by 263.58% to $51.2 million in 2025.
  • Its last three reported values are $51.2 million in Q3 2025, -$12.0 million for Q2 2025, and $68.0 million during Q1 2025.